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InﬂammationAbstract This study speciﬁcally focuses to investigate whether N-acetyl cysteine (NAC) has poten-
tial ameliorative effects against aspartame-induced brain pathophysiology in rats. Thirty adult male
Wistar rats weighing 200–220 g were randomly divided into three groups as follows: the ﬁrst group
was administered with distilled water and served as the control group; the second group was given
aspartame at a dose of 75 mg/kg b.wt. and the third group was given both aspartame and N-acetyl
cysteine at dose of 75 mg/kg b.wt. and 600 mg/kg b.wt. respectively. Oral administration was done
in the morning daily for 90 days.
Long term consumption of the artiﬁcial sweetener aspartame (ASP) induced large increments in
cortical inﬂammation and oxidative stress. Daily oral NAC administration can signiﬁcantly reverse
brain-derived neurotrophic factor (BDNF) levels, blocked the cyclooxygenase-2 (COX-2) and
prostaglandin E2 (PGE2) production with selective attenuation in expression of proinﬂammatory
cytokines of interleukin-6 (IL-6) and tumor necrosis factor-a (TNF-a) in the rat cerebral cortex.
Also, NAC can signiﬁcantly replenish and correct intracellular glutathione (GSH) levels, modulate
the elevated levels of total nitric oxide (TNO) and lipid peroxidation (LPO). Conclusions: The
present results amply support the concept that the brain oxidative stress and inﬂammation coexist
in experimental animals chronically treated with aspartame and they represent two distinct thera-
peutic targets in ASP toxicity. The present data propose that NAC attenuated ASP neurotoxicity
and improved neurological functions, suppressed brain inﬂammation, and oxidative stress
responses and may be a useful strategy for treating ASP-induced neurotoxicity.
ª 2015 The Egyptian German Society for Zoology. Production and hosting by Elsevier B.V. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
ASP is one of the most widely used artiﬁcial sweeteners in the
world. It is found in more than 6000 products including
74 A.A.S. Salehcarbonated and powdered soft drinks, hot chocolate, chewing
gum, candy, desserts, yogurt, and tabletop sweeteners, as well
as some pharmaceutical products like vitamins and sugar-free
cough drops. Artiﬁcial sweeteners, such as ASP, are therefore
often included in the diet of diabetic patients because these
compounds sweeten foods without adding calories or raising
blood glucose levels (Choudhary and Devi, 2015). In the
European Union, it is codiﬁed as E951. Currently, the accept-
able daily intake for humans is set at 50 mg/kg in the United
States and 40 mg/kg in Europe. It was previously shown that
ASP consumption, frequently used by diabetic patients, is a
potent inductor of cytochrome P450 (CYP) enzymes in the
brain of juvenile non diabetic rats (Vences-Mejı´a et al.,
2006). Recently, ASP consumption and insulin treatment in
a juvenile diabetic rat model leads to increase in CYP 2E1
and CYP3A2 isozymes in brain (Nosti-Palacios et al., 2014).
ASP is a methyl ester of the aspartic acid/phenylalanine
dipeptide. Aspartyl phenylalanine diketopiperazine, a type of
diketopiperazine (DKP), is created in products as ASP breaks
down over time. The safety of the long-term consumption of
ASP (75 mg/kg/day) for 24 weeks at doses equivalent to the
amount of ASP in approximately 10 L of beverage per day
was documented (Butchko et al., 2002). On the other hand,
some researchers found that 6 months after ASP was put into
carbonated beverages, 25% of the ASP had been converted to
DKP (Lim et al., 2006). This form of DKP would undergo a
nitrosation process in the stomach producing a type of
chemical that could cause brain tumors (Davis et al., 2008).
Additionally, long-term consumption of ASP leads to an
imbalance in the antioxidant/pro-oxidant status in the brain,
mainly through the mechanism involving the glutathione-
dependent system (Abhilash et al., 2013).
Following oral administration to humans and experimental
animals, ASP is rapidly and completely metabolized by intesti-
nal esterases and dipeptidases to aspartic acid, phenylalanine
and methanol, substances normally found in the diet and body
(Mourad and Noor, 2011). The aspartic acid in ASP is a well-
documented excitotoxin (Prakash et al., 2014). Excitotoxins
are usually amino acids, such as glutamate and aspartate.
Aspartate is a highly excitatory neurotransmitter and
phenylalanine is a precursor of catecholamines in the brain,
increased levels of these molecules could change the basic
activity level of the brain to an unhealthy state
(Nosti-Palacios et al., 2014). The methanol metabolized from
ASP is converted to formaldehyde and then formic acid
(Choudhary and Devi, 2015). Besides, ASP ingestion is
implicated in neurological problems and chronic exposure of
aspartame resulted in detectable methanol in blood (Simintzi
et al., 2008). Moreover, methanol per se and its metabolites
are responsible for the generation of oxidative stress in the
brain region (Iyyaswamy and Rathinasamy, 2012).
Furthermore, Chronic formaldehyde exposure at very low
doses has been shown to cause immune system and nervous
system changes and damage as well as headaches, general poor
health, irreversible genetic damage, memory loss, and a
number of other serious health problems (Sun-Edelstein and
Mauskop, 2009; Abdel-Salam et al., 2012b).
Excitotoxins are substances that react with specialized
receptors in the brain in such a way as to lead to destruction
of certain types of neurons. Despite evidence that glutamate,
aspartame and other food neurotoxic amino acids are
excitotoxins that can destroy central neurons following oralintake by animals of various species, this amino acid continues
to be one of the most vilely and heavily used food additives in
the world (Blaylock, 2002). Excitotoxins have a devastating
effect on formation of the brain (wiring of the brain) and
such an exposure can cause the brain to be miswired
(Soffritti et al., 2006). Also, the new-born rats prenatally
treated with ASP showed signiﬁcant increase of the LPO rate
and depletion of SH groups in the brain homogenate.
Further, ASP is a potential angiogenic agent that can induce
ROS production that stimulates induction of cytokines and
growth factors as it enhances IL-6, vascular endothelial growth
factor and their soluble receptors release from the endothelial
cells (Alleva et al., 2011) as well as brain oxidative stress
increased by repeated ASP administration (Abdel-Salam
et al., 2012a,b).
NAC is an acetylated variant of the amino acid L-cysteine,
is an effective antidote able to increase cell protection to oxida-
tive stress (Fries and Kapczinski, 2011). Moreover, NAC is an
effective scavenger of free radicals as it interacts with ROS
such as OH and H2O2 as well as a major contributor to
maintenance of the cellular GSH status and can minimize
the oxidative effect of ROS through correcting or preventing
GSH depletion. Further, NAC has been used successfully to
treat GSH deﬁciency in a wide range of infections, genetic
defects and metabolic disorders, including HIV infection and
chronic obstructive pulmonary disease (COPD) (Atkuri
et al., 2007). In addition, NAC has a broad spectrum of actions
and possible applications across multiple conditions and
systems (Duarte et al., 2012). As a drug, NAC represents
perhaps the ideal xenobiotic, capable of directly entering
endogenous biochemical processes as a result of its own
metabolism (Sahin and Alatas, 2013). Recent research has also
highlighted the fact that NAC may cross the blood–brain
barrier (BBB) and the most ‘‘exciting’’ work is in the ability
of NAC to heal brain dysfunctions and neuropathies and it
is now emerging as a treatment of vascular and nonvascular
neurological disorders, modulates glutamatergic, neurotrophic
and inﬂammatory pathways (Shahripour et al., 2014).
This study aims to evaluate the neuroameliorative effect of
NAC in response to inﬂammatory and oxidative stress caused
by chronic administration of ASP to rats.
Material and methods
Animals
The experimental animals were carried out after approval from
the Department of Zoology Council, Women’s College, Ain
Shams University, Egypt, which is an ethical authority.
Thirty adult male Wistar rats weighing 200–220 g were used
as experimental animals after being procured from the
Animal House of El-Nile Company for Pharmaceutical
Products, Cairo, Egypt. The animals were acclimatized for
2 weeks in the Animal House of Zoology Department,
Women’s College, Ain Shams University prior to the experi-
ment. They were fed to appetite on standard laboratory animal
rodent feed and water was available for animals ad libitum.
They were housed in a well ventilated animal house kept under
standard managerial and environmental conditions (12 h
light/dark cycles at 25 ± 2 C).
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Pure ASP powder and NAC were purchased from Sigma
Chem. Co., St. Louis, MO, USA.
Aspartame dose
ASP dissolved in distilled water was administered orally
(75 mg/kg b.wt.) and this dosage was ﬁxed as per Iyyaswamy
et al. (2013). In order to conﬁne the dosage within the human
exposure limit, this dose was selected and the chronic dose of
aspartame was given daily for 90 days.
N-acetylcysteine dose
NAC is available as a health supplement that is normally pro-
duced in capsule form. In the current study, the therapeutic
dose of NAC was applied (600 mg/kg b.wt/day) and this
dosage was ﬁxed based as per Saleh (2014). It was dissolved
in distilled water and was administered orally for 90 days.
Experimental design
Three groups were formed (n/10) for daily oral administration;
rats of the ﬁrst group were given distilled water throughout the
experimental period and served as the control group. Each rat
of the second group was given ASP in a dose of
75 mg/kg b.wt/day for 90 days. All the rats in the third group
were given both ASP (75 mg/kg b.wt/day) and NAC
(600 mg/kg b.wt/day) for the same period. After 90 days all
the animals were decapitated.
Cerebral cortex homogenates
After animal’s decapitation, the brain of each animal was
quickly removed and washed in ice-cold saline and rapidly
transferred to an ice-cold petri dish and dissected to obtain
the cerebral cortex. For the determination of rats BDNF,
COX-2, PGE2 and cytokines (IL-6 and TNF-a), one hundred
milligrams of cerebral cortex was homogenized in two volumes
of 0.01 mol/L phosphate buffered saline (PBS) containing
0.05% Tween-20. After homogenization and centrifugation
at 10,000 g at 4 C for 20 min, the resultant supernatant was
collected and stored at 680 C until use. The levels of
cerebral cortex BDNF, COX-2, PGE2 and cytokines
(IL-6 and TNF-a) were measured using a quantitative sand-
wich enzyme-linked immuno-sorbent assay (ELISA) withTable 1 Anti-neuroinﬂammatory effects of NAC on BDNF, COX
aspartame.
Parameters Control group
BDNF (pg/mg tissue) 57.549 ± 1.738a
COX-2 (ng/mg tissue) 0.758 ± 0.065a
PGE2 (pg/mg tissue) 12.946 ± 0.352
a
Values are expressed as means ± S.E, n= 10.
a Signiﬁcant at p< 0.05 between the groups in the same rows.
b Signiﬁcant at p< 0.05 between the groups in the same rows.
c Signiﬁcant at p< 0.05 between the groups in the same rows.monoclonal antibodies speciﬁc for rat BDNF, COX-2, PGE2
and cytokines (IL-6 and TNF-a). The commercial ELISA kit
of rat BDNF was purchased from WKEA Co. (UAS). The
commercial ELISA kit of rat COX-2, PGE2 and cytokines
(IL-6 and TNF-a) were purchased from Immuno-Biological
Laboratories Co., Ltd (IBL) USA.
Another, one hundred milligrams of cerebral cortex was
homogenized in ice-cold tri-hydrochloride buffer (pH 7.2) for
the estimation of GSH, TNO and LPO. The homogenate
was centrifuged at 800 g for 10 min, followed by centrifugation
of the supernatant at 12,000 g for 15 min. The supernatant was
removed for determination immediately or stored in aliquot at
680 C until assay. The commercial ELISA kit of GSH,
TNO and LPO were purchased from Oxford Biomedical
Research Inc., USA and analyses were carried out according
to Baker et al. (1990), Green et al. (1982) and Hogberg et al.
(1974), respectively.
Statistical analysis
Statistical deference between the means was assayed by using
analysis of variance (ANOVA) followed by Duncan’s multiple
range tests according to Snedecor and Cochran (1982).Result
This study demonstrates that chronic ASP consumption
(75 mg/kg b.wt/day) for 90 days signiﬁcantly increased brain
damage associated brain markers (BDNF, COX-2 and
PGE2) and elevated the production of cerebral cortex
cytokines, IL-6 and TNF-a, respectively. Moreover, the same
exposure reduced GSH levels, enhanced TNO production as
well as ROS generation and LPO of ASP-treated rats.
In the present data, administration of NAC showed a sig-
niﬁcant increment in BDNF level, signiﬁcantly inhibited the
production of COX-2 expression activity as well as modulation
of PGE2 level in cerebral cortex homogenates (Table 1) as
compared with the ASP group. NAC administration
(600 mg/kg b.wt/day) attenuated the release of IL-6 and
TNF-a (Table 2) with respect to the ASP group.
Administration of NAC, a cysteine prodrug, replenishes and
restored the depletion of intracellular GSH levels. In contrast,
NAC signiﬁcantly reduced two independent markers of oxida-
tive stress injury in the rat cerebral cortex, wherein the levels of
TNO (a reliable biomarker of inﬂammation) as well as LPO (a
reliable biomarker of lipid peroxidation) were both signiﬁ-
cantly ameliorated (Table 3) as compared to the ASP group.-2 and PGE2 in rat cerebral cortex in long-term consumption of
ASP group ASP + NAC group
30.216 ± 1.005b 42.873 ± 1.331c
1.332 ± 0.097b 0.841 ± 0.077c
23.593 ± 0.607b 16.685 ± 0.477c
Table 3 Antioxidant effects of NAC on GSH, TNO and LPO in rat cerebral cortex in long-term consumption of aspartame.
Parameters Control group ASP group ASP + NAC group
GSH (lM/mg tissue) 1.659 ± 0.092a 1.087 ± 0.068b 1.359 ± 0.077c
TNO (ng/mg tissue) 10.278 ± 0.638a 29.312 ± 1.709b 16.267 ± 0.862c
LPO (ng/mg tissue) 0.167 ± 0.008a 0.393 ± 0.014 b 0.241 ± 0.011c
Values are expressed as means ± S.E, n= 10.
a Signiﬁcant at p< 0.05 between the groups in the same rows.
b Signiﬁcant at p< 0.05 between the groups in the same rows.
c Signiﬁcant at p< 0.05 between the groups in the same rows.
Table 2 Anti-neuroinﬂammatory effects of NAC on IL-6 and TNF-a in rat cerebral cortex in long-term consumption of aspartame.
Parameters Control group ASP group ASP + NAC group
IL-6 (pg/mg tissue) 248.9 ± 11.412a 448.5 ± 17.227b 301.554 ± 13.912c
TNF-a (pg/mg tissue) 578.9 ± 13.391a 929.7 ± 18.657b 661.2 ± 15.019c
Values are expressed as means ± S.E, n= 10.
a Signiﬁcant at p< 0.05 between the groups in the same rows.
b Signiﬁcant at p< 0.05 between the groups in the same rows.
c Signiﬁcant at p< 0.05 between the groups in the same rows.
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A recent study reported that drinking a single diet cola
sweetened with ASP every day could increase one’s risk of
developing a lymphoma or leukemia (Soffritti et al., 2006)
and diet soda has adverse effects on the cerebellum of adult
female albino Wistar rats (Eluwa et al., 2013).
ASP is metabolized into three toxic molecules, phenylala-
nine (50%), aspartic acid (40%), and methanol (10%), which
are then absorbed into the circulation and various neurochem-
ical effects of ASP have been associated with increases in and
persistence of their metabolites in CNS; those levels are
controlled by the blood–brain barrier (BBB) (Humphries
et al., 2008). ASP may also be carcinogenic because at least
its metabolite diketopiperazine (DKP) can cause cancers in
the central nervous system such as glioblastoma, medulloblas-
tomas and meningiomas (Abhilash et al., 2013).
Neurotrophins are chemicals that help to stimulate and con-
trol neurogenesis. BDNF is a member of the ‘‘neurotrophin’’
family of growth factors, which are related to the canonical
‘‘nerve growth factor’’, NGF. BDNF acts on certain neurons
of the central nervous system and the peripheral nervous
system, helping to support the survival of existing neurons,
and encourage the growth and differentiation of new neurons
and synapses (Zuccato et al., 2001). In the brain, it is active in
the hippocampus, cerebral cortex, and basal forebrain, areas
vital to learning, memory, and higher thinking (Bekinschtein
et al., 2008).
ASP acts as a chemical stressor because it increases corti-
costerone level which has been shown to decrease the expres-
sion of BDNF in rats and if exposure is persistent, this leads
to an eventual atrophy of the hippocampus (Warner-Schmidt
and Duman, 2006). Atrophy of the hippocampus and other
limbic structures has been shown to take place in humans
suffering from chronic depression (Hwang et al., 2006).
BDNF has been implicated as a speciﬁc growth and differenti-
ation factor in the development of serotonergic neurons(Choudhary and Devi, 2015). BDNF has a pleiotropic proﬁle,
preserving cell viability and function, preventing neuronal
degeneration during stress, and acting as an antidepressant
(Lu et al., 2013), with actions occurring through the stimula-
tion of the tropomyosin-related kinase B (TrkB) receptor
(Feng et al., 2015). In the current study, daily oral administra-
tion of ASP (75 mg/kg b.wt/day) for 90 days signiﬁcantly
represses cortical BDNF suggesting that loss or alterations in
it may contribute to the pathogenesis of neuronal dysfunction
in chronic ASP administration and may be related to the
high or toxic concentrations of the sweetener metabolites.
Among the risks, the phenylalanine in ASP dissociates from
the ester bond and increases dopamine levels in the brain.
This can lead to symptoms of depression because it distorts
serotonin/dopamine balance and it can also lead to migraine
headaches and brain tumors through a similar mechanism
(Abdel-Salam et al., 2012a).
NAC administration increases BDNF expression in the rat
cortex and reverses the atrophy-induced by ASP administra-
tion. As far as it seems, NAC may be the ﬁrst pharmacological
intervention that increases mitochondrial resilience and pre-
vents allostatic load in psychiatry (Kapczinski et al., 2008).
Add-on NAC therapy improved a variety of disorders includ-
ing, schizophrenia, bipolar depression, unipolar depression
(Shungu, 2012). More speciﬁcally, its usefulness on depressive
episodes may be linked to innovative mechanisms of action,
which increases the interest in studying the mechanisms by
which this drug may present neuroprotective effects and more
than 20 clinical trials have employed NAC as an adjunctive
treatment in various psychiatric disorders (Sandhir et al.,
2012). Growing evidences indicate that endogenous oxidants
and antioxidant defense interact in a vicious cycle, play a
critical role in the pathogenesis of cognitive dysfunction
(Samuni et al., 2013). The effectiveness of NAC in preventing
cognitive impairment as well as mito-oxidative stress may
be considered as a potential agent in the management of
cognitive-related disorders (Hoffer et al., 2013). NAC also
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increases BDNF, which protects neurons and is important
for long-term learning and memory (Prakash et al., 2014).
Cyclooxygenases exist in two isoforms, COX-1 and COX-2
where the ﬁrst one is present in most cells as a constitutive
enzyme, while COX-2 is triggered by inﬂammatory stimuli.
Inﬂammation constitutes an additional contributor of neuro
degeneration. COX-2, the inducible isoform of cyclooxygenase
(COX), is a rate-limiting enzyme in prostanoid synthesis and
its expression is rapidly regulated in developing and adult fore
brain by physiological synaptic activity (Serrano et al., 2011).
Besides, COX-2 appears to be expressed exclusively in neurons
which play a role in inﬂammatory responses and neuronal
injury in the brain. Additionally, COX-2 expression has been
proposed as a marker for metastatic potential in certain
tumors in both animal and human models (Karim et al., 2005).
Prostanoids, mainly PGE2, are released in response to
inﬂammation and generally have pro-inﬂammatory actions.
PGE2 production in brain endothelial cells is thought to be a
critical link for triggering central nervous inﬂammatory
responses such as fever while suppression of these responses
is done through activation of hypothalamic–pituitary–adrenal
(HPA) axis and production of glucocorticoids. COX-2 and
PGE2 can also affect neuronal excitability (Rang et al., 2007).
In the present work, Inﬂammatory responses are elevated in
the brain that are represented by a signiﬁcant elevation of
cortical COX-2 and PGE2 reveals that chronic ASP
administration alters the enzyme activity by possible raise in
free radicals and the observed changes may be due to the
methanol or its metabolite (Iyyaswamy et al., 2013). The ame-
liorative mechanisms of NAC involve preventing free radical
production, mitochondrial dysfunction, and inﬂammation
(Shahripour et al., 2014). Finally, NAC inhibits COX-2
induced by ASP a neurotoxin component and regulate PGE2
metabolism (Table 1).
At the site of inﬂammation, leukocytes produce compound
known as cytokines. Cytokines are small soluble glycoproteins
that can be divided into pro-inﬂammatory and anti-
inﬂammatory. These exert local actions as signaling molecules
between immune cells, but they may also reach the blood
stream and target remote structures such as the brain leading
to activation of other inﬂammatory mediators (Monica
et al., 2001). For instance the pro-inﬂammatory cytokine
IL-1 is important for signaling and stimulation of production
of inﬂammatory mediators like prostaglandins. The cytokines
that have received most attention as important for immune-to-
brain communication are IL-IB, IL-6, and TNF-a (Engblom
et al., 2002).
IL-6 is an interleukin that acts as both a pro-inﬂammatory
cytokine and an anti-inﬂammatory myokine. It is secreted by T
cells and macrophages to stimulate immune response, e.g. dur-
ing infection and after trauma, especially burns or other tissue
damage leading to inﬂammation. It is capable of crossing the
BBB and initiating synthesis of PGE2 in the hypothalamus
(Ethell and Pasquale, 2005). IL-6 has been shown to lead to
several neurological diseases through its impact on epigenetic
modiﬁcation within the brain. The epigenetic effects of IL-6
have also been implicated in the pathology of depression.
The effects of IL-6 on depression are mediated through the
repression of BDNF expression in the brain (Hwang et al.,
2006). Altered BDNF function has been implicated in depres-
sion which is likely due to epigenetic modiﬁcation followingIL-6 upregulation and BDNF is a neutrophic factor implicated
in spine formation, density, and morphology of neurons
(Sharma et al., 2008). Increased IL-6, therefore, can hyperme-
thylate DNA sequences and subsequently decreases gene
expression through its effects on DNA methyltransferase-
1(DNMT1) expression (Foran et al., 2010). In addition,
Inﬂammation consists of increased vascular permeability and
extravasation of serum components; this holds true for periph-
eral nervous system as well as CNS tissue. The peripheral
inﬂammatory process was accompanied by microglial activa-
tion and TNF-a increase in the hippocampus (Riazi et al.,
2010). Moreover, TNF promotes the inﬂammatory response,
which, in turn, causes many of the clinical problems associated
with autoimmune disorders such as rheumatoid arthritis,
ankylosing spondylitis, inﬂammatory bowel disease, psoriasis,
hidradenitis suppurativa, refractory asthma and major depres-
sion (Dowlati et al., 2010).
The data of the present study indicated a signiﬁcant
increase in the expression of IL-6 and TNF-a in ASP group
and a correlation co exists between IL-6 and TNF and the
severity as well as toxicity of ASP metabolite, methanol or
formaldehyde may be the causative factors behind the changes
observed (Choudhary and Devi, 2015). These results suggest
that both cytokines had toxic effects on myelin, Schwann cells,
and endothelial cells, increased vascular permeability, and
broke down the BBB and blood–nerve barrier (BNB)
(Misawa et al., 2001). In the present study, IL-6 and TNF-a
were signiﬁcantly high, and the animals with high cytokine
levels showed a good response to the administration of
NAC. It is clear that NAC may act on the barrier to reinforce
the BBB and BNB functions and also the thiol antioxidants
such as NAC block the subsequent cytokine production from
epithelial cells and macrophages by a mechanism involving
increasing intracellular GSH and decreasing NF-jB activation
(Samuni et al., 2013; Beppu et al., 2015).
The BBB is a micro anatomic system of capillaries function-
ally coupled with parenchymal brain cell (Zlokovic, 2008). The
BBB controls the blood-to-brain exchange of nutrients, xeno-
biotics, blood components and cells, ultimately maintaining
the optimal brain milieu necessary for physiological neuronal
function and even the cytokines are not permitted to enter
(Abbott et al., 2010). A healthy brain requires a healthy
BBB and disturbance of the blood-to-brain equilibrium can
be a cause or consequence of central nervous system diseases
and the unique location of the BBB makes it susceptible to
both brain and peripheral pathophysiological triggers
(Neuwelt et al., 2011). Speciﬁc BBB dysfunctions occur when
circulating leukocytes bind at the intraluminal side of the
endothelium and this causes increased BBB permeability to
ions and proteins, brain edema, changes in the brain milieu,
altered neuroglial physiology, leukocyte–endothelial interac-
tions, faulty angiogenesis, hemodynamic changes leading to
energy mismatch and development of brain inﬂammation
(Marchi et al., 2012). This phenomenon may promote the
release of diffusible factors (e.g., nitric oxide or prostaglan-
dins) that can, in turn, have pathologic effects on neuronal
excitability. Recent evidence has suggested this mode of action
to play a role in the earlier stages of peripheral inﬂammation
(Riazi et al., 2010). Several reports directly demonstrate that
BBB damage or dysfunction promotes seizures, contributes
to epileptogenesis, and favors seizure recurrence in epileptics
(Tomkins et al., 2008; Raabe et al., 2012). This study indicated
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and do not enter the brain but instead induce production of
PGE2 that can enter the brain and forward the signal.
Additionally it has been proven that COX-2, which is critical
for PGE2 production, is activated in the brain vasculature in
response to ASP metabolites as mentioned by Choudhary
and Devi (2015).
Excitotoxins are molecules, such as monosodium glutamate
(MSG) and aspartate, that act as excitatory neurotransmitters,
and can lead to neurotoxicity when used in excess. Excitotoxin
toxicity is a major contributor to pathological cell death within
the nervous system and appears to be mediated by ROS and
the effect of the excitotoxins action in the oxidative stress
mechanisms is due to the loss of glutathione (Oja et al.,
2000). Oxidative ASP (an excitotoxin) toxicity is initiated by
high concentrations of extra cellular ASP metabolites (metha-
nol, aspartate and phenylalanine) that prevent cystine uptake
into the cells, followed by the depletion of intracellular cysteine
which is necessary for glutathione synthesis (Blaylock, 2002).
The present results propose that ASP (excitotoxic food addi-
tives) or its metabolites increase the permeability of BBB and
can bypass the blood barrier system and enter the brain in
toxic concentrations that produced brain lesions. In accor-
dance with the present results, previous study of the neurotoxic
action of ASP on neuronal brain structures, the chronic
administration demonstrates the high vulnerability of brain
structure and functionality to ASP or to its metabolites’
toxicity (Iyyaswamy and Rathinasamy, 2012) and the exposure
of brain rats to ASP results in the rapid depletion of cortical
GSH followed by an increase in ROS and with a diminishing
supply of GSH, there is an accumulation of excessive amounts
of ROS and ultimately cell death, (Abhilash et al., 2013).
Evidence is growing that glutathione has many physiologi-
cal functions including its involvement in the detoxiﬁcation of
ROS in brain. Disorders of GSH metabolism are common in
major neurodegenerative diseases showing GSH depletion
and increased levels of oxidative stress in the brain (Aoyama
and Nakaki, 2013). The current ﬁndings indicate that chronic
stress of ASP has been shown to induce inhibition in GSH con-
tent and decreased GSH levels may be due to mitochondrial
dysfunction and oxidative stress that increase the accumula-
tion of toxic forms of ASP (Fries and Kapczinski, 2011;
Ruszkiewicz and Albrecht, 2015). So, the present study sug-
gested that supplementation with NAC could protect against
ASP toxicity as well as reverses mitochondrial dysfunctions
(Table 3). On the other hand, NAC may cross the BBB and
exerts a preventive effect on ASP-induced neurotoxicity in rats
(Sandhir et al., 2012). Moreover, neuroameliorative properties
of NAC may be related to its neurogenesis-inducing ability,
which is likely related to mitochondria-protective mechanisms
(Kapczinski et al., 2008;Voloboueva et al., 2010; Samuni et al.,
2013).
The nitric oxide (NO), a nitrogen free radical, is produced
by a number of different cell types with a variety of biological
functions. Oxidative stress is considered to be crucial in the
neural degeneration and the toxicity of ROS can be further
increased by forming peroxynitrite (ONOOe), which is a
molecule that causes oxidation and nitration of tyrosine resi-
dues on proteins (Mourad and Noor, 2011).
It has been reported that not only the metabolites of
methanol but methanol per se as well is toxic to the brain
(Iyyaswamy and Rathinasamy, 2012). In the same manner, asigniﬁcant elevation of the TNO registered following ASP
administration (Table 3). In addition to NO, peroxynitrite
may be generated in ASP induced inﬂammation .The biologi-
cal activity and decomposition of peroxynitrite depend a great
deal on the cellular or chemical environment (presence of pro-
teins, thiols, glucose, the ratio of NO and superoxide, carbon
dioxide levels, and other factors), and these factors inﬂuence
its toxic potential (Iyyaswamy et al., 2013). Moreover, this
increase in H2O2 and nitric oxide after ASP consumption
could not be overlooked as mentioned by McCord (2000)
who stated that prolonged exposure to free radicals, even at
a low concentration may result in the damage of biologically
important molecules and the cells can be injured or killed when
the ROS generation over-whelms the cellular antioxidant
capacity (Vences-Mejı´a et al., 2006).
The present study demonstrated that NAC reduces the
development of ROS, the degree of lipid peroxidation and
the degree of inﬂammation in rats’ cerebral cortex treated with
ASP. All these ﬁndings support the view that NAC attenuates
the degree of inﬂammation and oxidative stress caused by
chronic ASP administration in rats (Arakawa and Ito, 2007).
Whereas several studies have described a biphasic effect of
NAC on oxidative stress, ultimately leading to the control of
free radicals on neuronal injury (Fries and Kapczinski, 2011).
Excitotoxins themselves can cause the generation of
numerous amounts of free radicals and that during the
process of lipid peroxidation a substance is produced called
4-hydroxynonenal. This chemical inhibits the glutamate trans-
porter, thus allowing glutamate to accumulate in the brain
(Liu, 2003). In fact, 40% of ASP breaks down into an
excitotoxic amino acid thus free radicals can cause membrane
damage through peroxidation of unsaturated fatty acids in the
phospholipids making up the cell membrane (Mourad and
Noor, 2011). Peroxidation of membrane is accompanied by
alteration of the structural and functional characteristics of
membranes (Iyyaswamy et al., 2013). They can also cause
damage to fundamental cellular components such as nucleic
acid lesions, gene damage, and gene repair activity, leading
to subsequent cell death by necrotic or apoptotic mode
(Nosti-Palacios et al., 2014).
ASP administration (75 mg/kg b.wt/day), resulted in a
marked increase in free radical generation in the rat brain
regions (Vences-Mejı´a et al., 2006). In the same manner, long
term ASP consumption for 90 days has been shown to induce
an increase of LPO in the rat cerebral cortex suggesting a
brain-speciﬁc response to ASP treatment (Table 3). In the cur-
rent work, the observed results support the toxic nature of
ASP when consumed repeatedly for a prolonged period on
membrane bound enzymes and oxidative stress markers
(Nosti-Palacios et al., 2014). This increase in free radical
may be the cause behind the decrease in the activity of mem-
brane bound ATPases as well as decrease in creatine kinase
activity, as lipid per oxidation alters the membrane integrity
(Iyyaswamy et al., 2013). Besides, ASP metabolites induced
amino acid imbalance within neuron micro environment, thus
producing ultimate damage (Beck et al., 2002). It is possible
that persistence of ASP status neurotoxicity may be due to
BBB damage and inﬂammatory processes (Abdel-Salam
et al., 2012a,b) and it could be suggested that ASP metabolite
entering the brain from the cerebrospinal ﬂuid or via the BBB
were responsible for neurotoxicity of ASP. Additionally, neu-
rotoxicity of ASP may be related to its roles in the initiation
Anti-neuroinﬂammatory and antioxidant effects of N-acetyl cysteine 79of lipid peroxidation, inactivation of a variety of enzymes, and
depletion of GSH. However, treatment with NAC effectively
counteracts ASP-induced oxidative stress and brain damage.
The effect of NAC is very likely to the prevention of endothe-
lial oxidant injury and hence preservation of endothelial bar-
rier functions. These results support the view that the over
production of reactive oxygen or nitrogen free radicals con-
tributes to chronic inﬂammation. Finally, the present study
proposes that administration of NAC may be useful in the
therapy of conditions associated with chronic inﬂammation
(Voloboueva et al., 2010).
In conclusion, it could be concluded from this study that,
NAC administration ameliorates brain injury development fol-
lowing chronic ASP administration to rats and speciﬁc
improvement in neurological function, selective attenuation
in expression of tissue pro inﬂammatory cytokines and oxida-
tive stress responses as well as enhancing of brain glutathione
levels. Moreover, the administration with a sulfur-containing
antioxidant such as NAC may provide a new neuroprotective
therapeutic strategy for ASP neurotoxicity.
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